Loading clinical trials...
Loading clinical trials...
"Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment "
Conditions
Interventions
Trastuzumab
Pertuzumab
+2 more
Locations
7
Italy
Policlinico Sant'Orsola Malpighi
Bologna, BO, Italy
Azienda Ospedaliero Universitaria di Ferrara - Arcispedale S. Anna
Ferrara, FE, Italy
IST San Martino
Genova, GE, Italy
Ospedale San Raffaele
Milan, MI, Italy
Istituto Europeo di Oncologia
Milan, MI, Italy
Arcispedale S.Maria Nuova A.O.Reggio Emilia
Reggio Emilia, RE, Italy
Start Date
May 1, 2015
Primary Completion Date
September 1, 2019
Completion Date
November 1, 2019
Last Updated
July 15, 2020
NCT07191730
NCT06797635
NCT06312176
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Fondazione Michelangelo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions